Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Cardiology

Journal Scan / Research · September 03, 2020

Vupanorsen Lowers Triglycerides and Atherogenic Lipoproteins in Patients With Diabetes, Hepatic Steatosis, and Hypertriglyceridemia

European Heart Journal

 

Additional Info

Disclosure statements are available on the authors' profiles:

European Heart Journal
Vupanorsen, an N-Acetyl Galactosamine-Conjugated Antisense Drug to ANGPTL3 mRNA, Lowers Triglycerides and Atherogenic Lipoproteins in Patients With Diabetes, Hepatic Steatosis, and Hypertriglyceridaemia
Eur Heart J 2020 Aug 29;[EPub Ahead of Print], D Gaudet, E Karwatowska-Prokopczuk, SJ Baum, E Hurh, J Kingsbury, VJ Bartlett, AL Figueroa, P Piscitelli, W Singleton, JL Witztum, RS Geary, S Tsimikas, L St L O'Dea

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading